Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11025470rdf:typepubmed:Citationlld:pubmed
pubmed-article:11025470lifeskim:mentionsumls-concept:C1513822lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C1880171lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C1456649lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0005767lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0376152lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0332835lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0472699lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0006463lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0015133lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0009647lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C1521725lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:11025470lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:11025470pubmed:issue4lld:pubmed
pubmed-article:11025470pubmed:dateCreated2000-10-18lld:pubmed
pubmed-article:11025470pubmed:abstractTextHematopoietic stem cell transplantation (HSCT) is an important treatment modality for children with AML. The optimal conditioning regimen is unknown. The aim of this study was to determine the appropriate dosing of etoposide in combination with busulfan and cyclophosphamide in this setting.lld:pubmed
pubmed-article:11025470pubmed:languageenglld:pubmed
pubmed-article:11025470pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11025470pubmed:citationSubsetIMlld:pubmed
pubmed-article:11025470pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11025470pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11025470pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11025470pubmed:statusMEDLINElld:pubmed
pubmed-article:11025470pubmed:monthOctlld:pubmed
pubmed-article:11025470pubmed:issn0098-1532lld:pubmed
pubmed-article:11025470pubmed:authorpubmed-author:WallDDlld:pubmed
pubmed-article:11025470pubmed:authorpubmed-author:CoppesM JMJlld:pubmed
pubmed-article:11025470pubmed:authorpubmed-author:KamaniNNlld:pubmed
pubmed-article:11025470pubmed:authorpubmed-author:MustafaM MMMlld:pubmed
pubmed-article:11025470pubmed:authorpubmed-author:SandlerE SESlld:pubmed
pubmed-article:11025470pubmed:authorpubmed-author:HaggRRlld:pubmed
pubmed-article:11025470pubmed:authorpubmed-author:GamisAAlld:pubmed
pubmed-article:11025470pubmed:copyrightInfoCopyright 2000 Wiley-Liss, Inc.lld:pubmed
pubmed-article:11025470pubmed:issnTypePrintlld:pubmed
pubmed-article:11025470pubmed:volume35lld:pubmed
pubmed-article:11025470pubmed:ownerNLMlld:pubmed
pubmed-article:11025470pubmed:authorsCompleteYlld:pubmed
pubmed-article:11025470pubmed:pagination403-9lld:pubmed
pubmed-article:11025470pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:meshHeadingpubmed-meshheading:11025470...lld:pubmed
pubmed-article:11025470pubmed:year2000lld:pubmed
pubmed-article:11025470pubmed:articleTitleHematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.lld:pubmed
pubmed-article:11025470pubmed:affiliationUT Southwestern Medical School and Children's Hospital of Dallas, Dallas, Texas, USA. esandler@nemours.orglld:pubmed
pubmed-article:11025470pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11025470pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11025470pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:11025470pubmed:publicationTypeClinical Trial, Phase Illd:pubmed